Literature DB >> 8847048

Aminopyrine breath test: development of a 13C-breath test for quantitative assessment of liver function in humans.

F Mion1, P E Queneau, M Rousseau, J L Brazier, P Paliard, Y Minaire.   

Abstract

BACKGROUND/AIM: 14C-aminopyrine breath test (ABT) has been shown to be well correlated to the severity of liver diseases, but its use is limited in countries where radioactive isotopes are severely controlled. The goal of this study was to develop a 13C-ABT based on a highly sensitive method to measure 13CO2 in breath samples.
MATERIALS AND METHODS: The relevant parameters were studied in 26 controls and 27 patients: the 13CO2 enrichment of expired breath between t-10 and t+60 minutes was determined as the most simple and clinically useful parameter. The 13C-ABT was then prospectively compared to clinico-biological data and the galactose elimination capacity (GEC) in 82 patients.
RESULTS: The 13C-ABT was well correlated to: i) the Child-Pugh classification; ii) GEC results; iii) the hepatic volume. The presence of ascites or alcoholic consumption did not alter significantly the results of the test. 13C-ABT appeared more sensitive than GEC to evaluate minor liver dysfunctions.
CONCLUSIONS: The 13C-ABT is a simple and sensitive test to measure liver function. The use of the stable isotope 13C ensures the harmlessness of the test and the possibility to repeat it in a given patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8847048

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test.

Authors:  Maciej Malinowski; Maximilian Jara; Katja Lüttgert; James Orr; Johan Friso Lock; Eckart Schott; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2014-07-04       Impact factor: 3.199

2.  Assessment of hepatic detoxification activity: proposal of an improved variant of the (13)c-methacetin breath test.

Authors:  Hermann-Georg Holzhütter; Johan Friso Lock; Pouria Taheri; Sascha Bulik; Andrean Goede; Martin Stockmann
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.